ACM
LAB icon

Aster Capital Management’s Standard BioTools LAB Stock Holding History

Aster Capital Management’s Portfolio LAB Stock Details LAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-78
Closed -$137 – 1482
2024
Q4 		$137 Buy
78
+19
+32% +$35 ﹤0.01% 1068
2024
Q3 		$114 Buy
+59
New +$116 ﹤0.01% 1067

Other funds holding LAB

CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
TM
Tikvah Management Charlotte, North Carolina $323M AUM 69.61% 1-Year Est. Return
MFS
Mirabella Financial Services London, United Kingdom $1.06B AUM 19.83% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Aster Capital Management's LAB Position: Q1 2025 in Review

Aster Capital Management sold out of Standard BioTools (LAB) in Q1 2025, closing a stake of 78 shares — an estimated $137 sold.

Aster Capital Management first reported a position in LAB in Q3 2024 and held it in 2 quarters. The position peaked at $137 in Q4 2024. 145 funds tracked by Wall St. Rank hold LAB as of Q1 2025.

  • Aster Capital Management reported no remaining Standard BioTools position as of Q1 2025 after selling out during the quarter.
  • Aster Capital Management sold 78 Standard BioTools shares in Q1 2025, an estimated $137.
  • Aster Capital Management first reported a position in Standard BioTools in Q3 2024 and held it in 2 quarters.
  • Aster Capital Management's Standard BioTools position peaked at $137 in Q4 2024.
  • 145 funds tracked by Wall St. Rank held Standard BioTools as of Q1 2025.

Based on Aster Capital Management's 13F filing for Q1 2025, filed 15 May 2025.